Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population.
Autor*in: |
Zhu, Andrew X [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2018 |
---|
Umfang: |
13 |
---|
Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
---|---|
Übergeordnetes Werk: |
volume:19 ; year:2018 ; number:7 ; pages:940-952 ; extent:13 |
Links: |
---|
DOI / URN: |
10.1016/S1470-2045(18)30351-6 |
---|
Katalog-ID: |
ELV043614124 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV043614124 | ||
003 | DE-627 | ||
005 | 20230624104408.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180726s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/S1470-2045(18)30351-6 |2 doi | |
028 | 5 | 2 | |a GBV00000000000347.pica |
035 | |a (DE-627)ELV043614124 | ||
035 | |a (ELSEVIER)S1470-2045(18)30351-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 570 |q VZ |
084 | |a BIODIV |q DE-30 |2 fid | ||
084 | |a 35.70 |2 bkl | ||
084 | |a 42.12 |2 bkl | ||
100 | 1 | |a Zhu, Andrew X |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial |
264 | 1 | |c 2018 | |
300 | |a 13 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. | ||
700 | 1 | |a Finn, Richard S |4 oth | |
700 | 1 | |a Edeline, Julien |4 oth | |
700 | 1 | |a Cattan, Stephane |4 oth | |
700 | 1 | |a Ogasawara, Sadahisa |4 oth | |
700 | 1 | |a Palmer, Daniel |4 oth | |
700 | 1 | |a Verslype, Chris |4 oth | |
700 | 1 | |a Zagonel, Vittorina |4 oth | |
700 | 1 | |a Fartoux, Laetitia |4 oth | |
700 | 1 | |a Vogel, Arndt |4 oth | |
700 | 1 | |a Sarker, Debashis |4 oth | |
700 | 1 | |a Verset, Gontran |4 oth | |
700 | 1 | |a Chan, Stephen L |4 oth | |
700 | 1 | |a Knox, Jennifer |4 oth | |
700 | 1 | |a Daniele, Bruno |4 oth | |
700 | 1 | |a Webber, Andrea L |4 oth | |
700 | 1 | |a Ebbinghaus, Scot W |4 oth | |
700 | 1 | |a Ma, Junshui |4 oth | |
700 | 1 | |a Siegel, Abby B |4 oth | |
700 | 1 | |a Cheng, Ann-Lii |4 oth | |
700 | 1 | |a Kudo, Masatoshi |4 oth | |
700 | 1 | |a Alistar, Angela |4 oth | |
700 | 1 | |a Asselah, Jamil |4 oth | |
700 | 1 | |a Blanc, Jean-Frederic |4 oth | |
700 | 1 | |a Borbath, Ivan |4 oth | |
700 | 1 | |a Cannon, Timothy |4 oth | |
700 | 1 | |a Chung, Ki |4 oth | |
700 | 1 | |a Cohn, Allen |4 oth | |
700 | 1 | |a Cosgrove, David P |4 oth | |
700 | 1 | |a Damjanov, Nevena |4 oth | |
700 | 1 | |a Gupta, Mukul |4 oth | |
700 | 1 | |a Karino, Yoshivasu |4 oth | |
700 | 1 | |a Karwal, Mark |4 oth | |
700 | 1 | |a Kaubisch, Andreas |4 oth | |
700 | 1 | |a Kelley, Robin |4 oth | |
700 | 1 | |a Van Laethem, Jena-Luc |4 oth | |
700 | 1 | |a Larson, Timothy |4 oth | |
700 | 1 | |a Lee, James |4 oth | |
700 | 1 | |a Li, Daneng |4 oth | |
700 | 1 | |a Manhas, Atisha |4 oth | |
700 | 1 | |a Manji, Gulam Abbas |4 oth | |
700 | 1 | |a Numata, Kazushi |4 oth | |
700 | 1 | |a Parsons, Benjamin |4 oth | |
700 | 1 | |a Paulson, Andrew S. |4 oth | |
700 | 1 | |a Pinto, Carmine |4 oth | |
700 | 1 | |a Ramirez, Robert |4 oth | |
700 | 1 | |a Ratnam, Suresh |4 oth | |
700 | 1 | |a Rizell, Magnus |4 oth | |
700 | 1 | |a Rosmorduc, Olivier |4 oth | |
700 | 1 | |a Sada, Yvonne |4 oth | |
700 | 1 | |a Sasaki, Yutaka |4 oth | |
700 | 1 | |a Stal, Per I |4 oth | |
700 | 1 | |a Strasser, Simone |4 oth | |
700 | 1 | |a Trojan, Joerg |4 oth | |
700 | 1 | |a Vaccaro, Gina |4 oth | |
700 | 1 | |a Van Vlierberghe, Hans |4 oth | |
700 | 1 | |a Weiss, Alan |4 oth | |
700 | 1 | |a Weiss, Karl-Heinz |4 oth | |
700 | 1 | |a Yamashita, Tatsuya |4 oth | |
773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
773 | 1 | 8 | |g volume:19 |g year:2018 |g number:7 |g pages:940-952 |g extent:13 |
856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(18)30351-6 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a FID-BIODIV | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
936 | b | k | |a 42.12 |j Biophysik |q VZ |
951 | |a AR | ||
952 | |d 19 |j 2018 |e 7 |h 940-952 |g 13 |
author_variant |
a x z ax axz |
---|---|
matchkey_str |
zhuandrewxfinnrichardsedelinejuliencatta:2018----:eboiuaiptetwtavnehptcluacrioarvosyraewtsrfnbent24 |
hierarchy_sort_str |
2018 |
bklnumber |
35.70 42.12 |
publishDate |
2018 |
allfields |
10.1016/S1470-2045(18)30351-6 doi GBV00000000000347.pica (DE-627)ELV043614124 (ELSEVIER)S1470-2045(18)30351-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Zhu, Andrew X verfasserin aut Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial 2018 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Finn, Richard S oth Edeline, Julien oth Cattan, Stephane oth Ogasawara, Sadahisa oth Palmer, Daniel oth Verslype, Chris oth Zagonel, Vittorina oth Fartoux, Laetitia oth Vogel, Arndt oth Sarker, Debashis oth Verset, Gontran oth Chan, Stephen L oth Knox, Jennifer oth Daniele, Bruno oth Webber, Andrea L oth Ebbinghaus, Scot W oth Ma, Junshui oth Siegel, Abby B oth Cheng, Ann-Lii oth Kudo, Masatoshi oth Alistar, Angela oth Asselah, Jamil oth Blanc, Jean-Frederic oth Borbath, Ivan oth Cannon, Timothy oth Chung, Ki oth Cohn, Allen oth Cosgrove, David P oth Damjanov, Nevena oth Gupta, Mukul oth Karino, Yoshivasu oth Karwal, Mark oth Kaubisch, Andreas oth Kelley, Robin oth Van Laethem, Jena-Luc oth Larson, Timothy oth Lee, James oth Li, Daneng oth Manhas, Atisha oth Manji, Gulam Abbas oth Numata, Kazushi oth Parsons, Benjamin oth Paulson, Andrew S. oth Pinto, Carmine oth Ramirez, Robert oth Ratnam, Suresh oth Rizell, Magnus oth Rosmorduc, Olivier oth Sada, Yvonne oth Sasaki, Yutaka oth Stal, Per I oth Strasser, Simone oth Trojan, Joerg oth Vaccaro, Gina oth Van Vlierberghe, Hans oth Weiss, Alan oth Weiss, Karl-Heinz oth Yamashita, Tatsuya oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:19 year:2018 number:7 pages:940-952 extent:13 https://doi.org/10.1016/S1470-2045(18)30351-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 19 2018 7 940-952 13 |
spelling |
10.1016/S1470-2045(18)30351-6 doi GBV00000000000347.pica (DE-627)ELV043614124 (ELSEVIER)S1470-2045(18)30351-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Zhu, Andrew X verfasserin aut Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial 2018 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Finn, Richard S oth Edeline, Julien oth Cattan, Stephane oth Ogasawara, Sadahisa oth Palmer, Daniel oth Verslype, Chris oth Zagonel, Vittorina oth Fartoux, Laetitia oth Vogel, Arndt oth Sarker, Debashis oth Verset, Gontran oth Chan, Stephen L oth Knox, Jennifer oth Daniele, Bruno oth Webber, Andrea L oth Ebbinghaus, Scot W oth Ma, Junshui oth Siegel, Abby B oth Cheng, Ann-Lii oth Kudo, Masatoshi oth Alistar, Angela oth Asselah, Jamil oth Blanc, Jean-Frederic oth Borbath, Ivan oth Cannon, Timothy oth Chung, Ki oth Cohn, Allen oth Cosgrove, David P oth Damjanov, Nevena oth Gupta, Mukul oth Karino, Yoshivasu oth Karwal, Mark oth Kaubisch, Andreas oth Kelley, Robin oth Van Laethem, Jena-Luc oth Larson, Timothy oth Lee, James oth Li, Daneng oth Manhas, Atisha oth Manji, Gulam Abbas oth Numata, Kazushi oth Parsons, Benjamin oth Paulson, Andrew S. oth Pinto, Carmine oth Ramirez, Robert oth Ratnam, Suresh oth Rizell, Magnus oth Rosmorduc, Olivier oth Sada, Yvonne oth Sasaki, Yutaka oth Stal, Per I oth Strasser, Simone oth Trojan, Joerg oth Vaccaro, Gina oth Van Vlierberghe, Hans oth Weiss, Alan oth Weiss, Karl-Heinz oth Yamashita, Tatsuya oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:19 year:2018 number:7 pages:940-952 extent:13 https://doi.org/10.1016/S1470-2045(18)30351-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 19 2018 7 940-952 13 |
allfields_unstemmed |
10.1016/S1470-2045(18)30351-6 doi GBV00000000000347.pica (DE-627)ELV043614124 (ELSEVIER)S1470-2045(18)30351-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Zhu, Andrew X verfasserin aut Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial 2018 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Finn, Richard S oth Edeline, Julien oth Cattan, Stephane oth Ogasawara, Sadahisa oth Palmer, Daniel oth Verslype, Chris oth Zagonel, Vittorina oth Fartoux, Laetitia oth Vogel, Arndt oth Sarker, Debashis oth Verset, Gontran oth Chan, Stephen L oth Knox, Jennifer oth Daniele, Bruno oth Webber, Andrea L oth Ebbinghaus, Scot W oth Ma, Junshui oth Siegel, Abby B oth Cheng, Ann-Lii oth Kudo, Masatoshi oth Alistar, Angela oth Asselah, Jamil oth Blanc, Jean-Frederic oth Borbath, Ivan oth Cannon, Timothy oth Chung, Ki oth Cohn, Allen oth Cosgrove, David P oth Damjanov, Nevena oth Gupta, Mukul oth Karino, Yoshivasu oth Karwal, Mark oth Kaubisch, Andreas oth Kelley, Robin oth Van Laethem, Jena-Luc oth Larson, Timothy oth Lee, James oth Li, Daneng oth Manhas, Atisha oth Manji, Gulam Abbas oth Numata, Kazushi oth Parsons, Benjamin oth Paulson, Andrew S. oth Pinto, Carmine oth Ramirez, Robert oth Ratnam, Suresh oth Rizell, Magnus oth Rosmorduc, Olivier oth Sada, Yvonne oth Sasaki, Yutaka oth Stal, Per I oth Strasser, Simone oth Trojan, Joerg oth Vaccaro, Gina oth Van Vlierberghe, Hans oth Weiss, Alan oth Weiss, Karl-Heinz oth Yamashita, Tatsuya oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:19 year:2018 number:7 pages:940-952 extent:13 https://doi.org/10.1016/S1470-2045(18)30351-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 19 2018 7 940-952 13 |
allfieldsGer |
10.1016/S1470-2045(18)30351-6 doi GBV00000000000347.pica (DE-627)ELV043614124 (ELSEVIER)S1470-2045(18)30351-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Zhu, Andrew X verfasserin aut Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial 2018 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Finn, Richard S oth Edeline, Julien oth Cattan, Stephane oth Ogasawara, Sadahisa oth Palmer, Daniel oth Verslype, Chris oth Zagonel, Vittorina oth Fartoux, Laetitia oth Vogel, Arndt oth Sarker, Debashis oth Verset, Gontran oth Chan, Stephen L oth Knox, Jennifer oth Daniele, Bruno oth Webber, Andrea L oth Ebbinghaus, Scot W oth Ma, Junshui oth Siegel, Abby B oth Cheng, Ann-Lii oth Kudo, Masatoshi oth Alistar, Angela oth Asselah, Jamil oth Blanc, Jean-Frederic oth Borbath, Ivan oth Cannon, Timothy oth Chung, Ki oth Cohn, Allen oth Cosgrove, David P oth Damjanov, Nevena oth Gupta, Mukul oth Karino, Yoshivasu oth Karwal, Mark oth Kaubisch, Andreas oth Kelley, Robin oth Van Laethem, Jena-Luc oth Larson, Timothy oth Lee, James oth Li, Daneng oth Manhas, Atisha oth Manji, Gulam Abbas oth Numata, Kazushi oth Parsons, Benjamin oth Paulson, Andrew S. oth Pinto, Carmine oth Ramirez, Robert oth Ratnam, Suresh oth Rizell, Magnus oth Rosmorduc, Olivier oth Sada, Yvonne oth Sasaki, Yutaka oth Stal, Per I oth Strasser, Simone oth Trojan, Joerg oth Vaccaro, Gina oth Van Vlierberghe, Hans oth Weiss, Alan oth Weiss, Karl-Heinz oth Yamashita, Tatsuya oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:19 year:2018 number:7 pages:940-952 extent:13 https://doi.org/10.1016/S1470-2045(18)30351-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 19 2018 7 940-952 13 |
allfieldsSound |
10.1016/S1470-2045(18)30351-6 doi GBV00000000000347.pica (DE-627)ELV043614124 (ELSEVIER)S1470-2045(18)30351-6 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Zhu, Andrew X verfasserin aut Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial 2018 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Finn, Richard S oth Edeline, Julien oth Cattan, Stephane oth Ogasawara, Sadahisa oth Palmer, Daniel oth Verslype, Chris oth Zagonel, Vittorina oth Fartoux, Laetitia oth Vogel, Arndt oth Sarker, Debashis oth Verset, Gontran oth Chan, Stephen L oth Knox, Jennifer oth Daniele, Bruno oth Webber, Andrea L oth Ebbinghaus, Scot W oth Ma, Junshui oth Siegel, Abby B oth Cheng, Ann-Lii oth Kudo, Masatoshi oth Alistar, Angela oth Asselah, Jamil oth Blanc, Jean-Frederic oth Borbath, Ivan oth Cannon, Timothy oth Chung, Ki oth Cohn, Allen oth Cosgrove, David P oth Damjanov, Nevena oth Gupta, Mukul oth Karino, Yoshivasu oth Karwal, Mark oth Kaubisch, Andreas oth Kelley, Robin oth Van Laethem, Jena-Luc oth Larson, Timothy oth Lee, James oth Li, Daneng oth Manhas, Atisha oth Manji, Gulam Abbas oth Numata, Kazushi oth Parsons, Benjamin oth Paulson, Andrew S. oth Pinto, Carmine oth Ramirez, Robert oth Ratnam, Suresh oth Rizell, Magnus oth Rosmorduc, Olivier oth Sada, Yvonne oth Sasaki, Yutaka oth Stal, Per I oth Strasser, Simone oth Trojan, Joerg oth Vaccaro, Gina oth Van Vlierberghe, Hans oth Weiss, Alan oth Weiss, Karl-Heinz oth Yamashita, Tatsuya oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:19 year:2018 number:7 pages:940-952 extent:13 https://doi.org/10.1016/S1470-2045(18)30351-6 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 19 2018 7 940-952 13 |
language |
English |
source |
Enthalten in My London volume:19 year:2018 number:7 pages:940-952 extent:13 |
sourceStr |
Enthalten in My London volume:19 year:2018 number:7 pages:940-952 extent:13 |
format_phy_str_mv |
Article |
bklname |
Biochemie: Allgemeines Biophysik |
institution |
findex.gbv.de |
dewey-raw |
570 |
isfreeaccess_bool |
false |
container_title |
My |
authorswithroles_txt_mv |
Zhu, Andrew X @@aut@@ Finn, Richard S @@oth@@ Edeline, Julien @@oth@@ Cattan, Stephane @@oth@@ Ogasawara, Sadahisa @@oth@@ Palmer, Daniel @@oth@@ Verslype, Chris @@oth@@ Zagonel, Vittorina @@oth@@ Fartoux, Laetitia @@oth@@ Vogel, Arndt @@oth@@ Sarker, Debashis @@oth@@ Verset, Gontran @@oth@@ Chan, Stephen L @@oth@@ Knox, Jennifer @@oth@@ Daniele, Bruno @@oth@@ Webber, Andrea L @@oth@@ Ebbinghaus, Scot W @@oth@@ Ma, Junshui @@oth@@ Siegel, Abby B @@oth@@ Cheng, Ann-Lii @@oth@@ Kudo, Masatoshi @@oth@@ Alistar, Angela @@oth@@ Asselah, Jamil @@oth@@ Blanc, Jean-Frederic @@oth@@ Borbath, Ivan @@oth@@ Cannon, Timothy @@oth@@ Chung, Ki @@oth@@ Cohn, Allen @@oth@@ Cosgrove, David P @@oth@@ Damjanov, Nevena @@oth@@ Gupta, Mukul @@oth@@ Karino, Yoshivasu @@oth@@ Karwal, Mark @@oth@@ Kaubisch, Andreas @@oth@@ Kelley, Robin @@oth@@ Van Laethem, Jena-Luc @@oth@@ Larson, Timothy @@oth@@ Lee, James @@oth@@ Li, Daneng @@oth@@ Manhas, Atisha @@oth@@ Manji, Gulam Abbas @@oth@@ Numata, Kazushi @@oth@@ Parsons, Benjamin @@oth@@ Paulson, Andrew S. @@oth@@ Pinto, Carmine @@oth@@ Ramirez, Robert @@oth@@ Ratnam, Suresh @@oth@@ Rizell, Magnus @@oth@@ Rosmorduc, Olivier @@oth@@ Sada, Yvonne @@oth@@ Sasaki, Yutaka @@oth@@ Stal, Per I @@oth@@ Strasser, Simone @@oth@@ Trojan, Joerg @@oth@@ Vaccaro, Gina @@oth@@ Van Vlierberghe, Hans @@oth@@ Weiss, Alan @@oth@@ Weiss, Karl-Heinz @@oth@@ Yamashita, Tatsuya @@oth@@ |
publishDateDaySort_date |
2018-01-01T00:00:00Z |
hierarchy_top_id |
ELV003173852 |
dewey-sort |
3570 |
id |
ELV043614124 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043614124</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624104408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(18)30351-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000347.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043614124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(18)30351-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhu, Andrew X</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finn, Richard S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Edeline, Julien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cattan, Stephane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ogasawara, Sadahisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palmer, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verslype, Chris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zagonel, Vittorina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fartoux, Laetitia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vogel, Arndt</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sarker, Debashis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verset, Gontran</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chan, Stephen L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knox, Jennifer</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Daniele, Bruno</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Webber, Andrea L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ebbinghaus, Scot W</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Junshui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Siegel, Abby B</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheng, Ann-Lii</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kudo, Masatoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alistar, Angela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Asselah, Jamil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blanc, Jean-Frederic</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borbath, Ivan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cannon, Timothy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chung, Ki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cohn, Allen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cosgrove, David P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damjanov, Nevena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Mukul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karino, Yoshivasu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karwal, Mark</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaubisch, Andreas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kelley, Robin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Laethem, Jena-Luc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larson, Timothy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Daneng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manhas, Atisha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manji, Gulam Abbas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Numata, Kazushi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parsons, Benjamin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paulson, Andrew S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pinto, Carmine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramirez, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ratnam, Suresh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rizell, Magnus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosmorduc, Olivier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sada, Yvonne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sasaki, Yutaka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stal, Per I</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strasser, Simone</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trojan, Joerg</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaccaro, Gina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Vlierberghe, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Alan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Karl-Heinz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamashita, Tatsuya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:940-952</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(18)30351-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2018</subfield><subfield code="e">7</subfield><subfield code="h">940-952</subfield><subfield code="g">13</subfield></datafield></record></collection>
|
author |
Zhu, Andrew X |
spellingShingle |
Zhu, Andrew X ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial |
authorStr |
Zhu, Andrew X |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
format |
electronic Article |
dewey-ones |
570 - Life sciences; biology |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial |
topic |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
topic_unstemmed |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
topic_browse |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
r s f rs rsf j e je s c sc s o so d p dp c v cv v z vz l f lf a v av d s ds g v gv s l c sl slc j k jk b d bd a l w al alw s w e sw swe j m jm a b s ab abs a l c alc m k mk a a aa j a ja j f b jfb i b ib t c tc k c kc a c ac d p c dp dpc n d nd m g mg y k yk m k mk a k ak r k rk l j l v ljl ljlv t l tl j l jl d l dl a m am g a m ga gam k n kn b p bp a s p as asp c p cp r r rr s r sr m r mr o r or y s ys y s ys p i s pi pis s s ss j t jt g v gv v h v vh vhv a w aw k h w khw t y ty |
hierarchy_parent_title |
My |
hierarchy_parent_id |
ELV003173852 |
dewey-tens |
570 - Life sciences; biology |
hierarchy_top_title |
My |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV003173852 |
title |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial |
ctrlnum |
(DE-627)ELV043614124 (ELSEVIER)S1470-2045(18)30351-6 |
title_full |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial |
author_sort |
Zhu, Andrew X |
journal |
My |
journalStr |
My |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
500 - Science |
recordtype |
marc |
publishDateSort |
2018 |
contenttype_str_mv |
zzz |
container_start_page |
940 |
author_browse |
Zhu, Andrew X |
container_volume |
19 |
physical |
13 |
class |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Zhu, Andrew X |
doi_str_mv |
10.1016/S1470-2045(18)30351-6 |
dewey-full |
570 |
title_sort |
pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (keynote-224): a non-randomised, open-label phase 2 trial |
title_auth |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial |
abstract |
Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. |
abstractGer |
Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. |
abstract_unstemmed |
Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
container_issue |
7 |
title_short |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial |
url |
https://doi.org/10.1016/S1470-2045(18)30351-6 |
remote_bool |
true |
author2 |
Finn, Richard S Edeline, Julien Cattan, Stephane Ogasawara, Sadahisa Palmer, Daniel Verslype, Chris Zagonel, Vittorina Fartoux, Laetitia Vogel, Arndt Sarker, Debashis Verset, Gontran Chan, Stephen L Knox, Jennifer Daniele, Bruno Webber, Andrea L Ebbinghaus, Scot W Ma, Junshui Siegel, Abby B Cheng, Ann-Lii Kudo, Masatoshi Alistar, Angela Asselah, Jamil Blanc, Jean-Frederic Borbath, Ivan Cannon, Timothy Chung, Ki Cohn, Allen Cosgrove, David P Damjanov, Nevena Gupta, Mukul Karino, Yoshivasu Karwal, Mark Kaubisch, Andreas Kelley, Robin Van Laethem, Jena-Luc Larson, Timothy Lee, James Li, Daneng Manhas, Atisha Manji, Gulam Abbas Numata, Kazushi Parsons, Benjamin Paulson, Andrew S. Pinto, Carmine Ramirez, Robert Ratnam, Suresh Rizell, Magnus Rosmorduc, Olivier Sada, Yvonne Sasaki, Yutaka Stal, Per I Strasser, Simone Trojan, Joerg Vaccaro, Gina Van Vlierberghe, Hans Weiss, Alan Weiss, Karl-Heinz Yamashita, Tatsuya |
author2Str |
Finn, Richard S Edeline, Julien Cattan, Stephane Ogasawara, Sadahisa Palmer, Daniel Verslype, Chris Zagonel, Vittorina Fartoux, Laetitia Vogel, Arndt Sarker, Debashis Verset, Gontran Chan, Stephen L Knox, Jennifer Daniele, Bruno Webber, Andrea L Ebbinghaus, Scot W Ma, Junshui Siegel, Abby B Cheng, Ann-Lii Kudo, Masatoshi Alistar, Angela Asselah, Jamil Blanc, Jean-Frederic Borbath, Ivan Cannon, Timothy Chung, Ki Cohn, Allen Cosgrove, David P Damjanov, Nevena Gupta, Mukul Karino, Yoshivasu Karwal, Mark Kaubisch, Andreas Kelley, Robin Van Laethem, Jena-Luc Larson, Timothy Lee, James Li, Daneng Manhas, Atisha Manji, Gulam Abbas Numata, Kazushi Parsons, Benjamin Paulson, Andrew S. Pinto, Carmine Ramirez, Robert Ratnam, Suresh Rizell, Magnus Rosmorduc, Olivier Sada, Yvonne Sasaki, Yutaka Stal, Per I Strasser, Simone Trojan, Joerg Vaccaro, Gina Van Vlierberghe, Hans Weiss, Alan Weiss, Karl-Heinz Yamashita, Tatsuya |
ppnlink |
ELV003173852 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
doi_str |
10.1016/S1470-2045(18)30351-6 |
up_date |
2024-07-06T19:17:23.884Z |
_version_ |
1803858418216206336 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043614124</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624104408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(18)30351-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000347.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043614124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(18)30351-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhu, Andrew X</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finn, Richard S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Edeline, Julien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cattan, Stephane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ogasawara, Sadahisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palmer, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verslype, Chris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zagonel, Vittorina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fartoux, Laetitia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vogel, Arndt</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sarker, Debashis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verset, Gontran</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chan, Stephen L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knox, Jennifer</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Daniele, Bruno</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Webber, Andrea L</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ebbinghaus, Scot W</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Junshui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Siegel, Abby B</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheng, Ann-Lii</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kudo, Masatoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alistar, Angela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Asselah, Jamil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blanc, Jean-Frederic</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borbath, Ivan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cannon, Timothy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chung, Ki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cohn, Allen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cosgrove, David P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damjanov, Nevena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gupta, Mukul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karino, Yoshivasu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karwal, Mark</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaubisch, Andreas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kelley, Robin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Laethem, Jena-Luc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larson, Timothy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Daneng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manhas, Atisha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manji, Gulam Abbas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Numata, Kazushi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parsons, Benjamin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paulson, Andrew S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pinto, Carmine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramirez, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ratnam, Suresh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rizell, Magnus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosmorduc, Olivier</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sada, Yvonne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sasaki, Yutaka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stal, Per I</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strasser, Simone</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trojan, Joerg</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaccaro, Gina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Vlierberghe, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Alan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Karl-Heinz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamashita, Tatsuya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:940-952</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(18)30351-6</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2018</subfield><subfield code="e">7</subfield><subfield code="h">940-952</subfield><subfield code="g">13</subfield></datafield></record></collection>
|
score |
7.39787 |